Viewing nowCombinationSebiten Tablets 5/20 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.

MFDS item code 201406189 · Approved 2014.12.31 · Insurance code 678600320
Treatment of essential hypertension not controlled with monotherapy
This medication can be used in patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy using either amlodipine or olmesartan medoxomil, allowing effective control of blood pressure. This reduces the risk of complications due to hypertension and improves overall cardiovascular health. This medication is used for the treatment of essential hypertension.
Administer 1 tablet once daily with water, regardless of meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medicine must not be administered in Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Pediatric patients: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. This medication should not be used by individuals who are allergic to the active ingredients or similar components, pregnant women, nursing mothers, patients with severe liver dysfunction, patients with severe aortic stenosis, patients with bile duct obstruction, patients undergoing renal dialysis, patients in a state of shock, certain diabetic patients, and patients with severely impaired kidney function. Careful observation is required when this medication is first administered to patients with deficient fluid or sodium levels, as hypotension may occur; appropriate management should be provided if hypotension occurs. Acute hypotension may rarely occur due to vascular dilation, so caution is necessary, especially in patients with severe heart valve disease. Patients with coronary artery disease or congestive heart failure should use this medication with caution, and patients with impaired kidney function should also be observed carefully. Since this medication is metabolized in the liver, it should be administered cautiously in patients with severe liver impairment. Side effects such as dizziness, headache, lowered blood pressure, cough, digestive disturbances, skin rashes, and edema may occur; if symptoms are severe, consult a physician. This medication should not be taken during pregnancy, and especially during the second and third trimesters, as it can pose serious risks to the fetus; patients planning to become pregnant or who are pregnant must consult a physician. Nursing mothers should discontinue breastfeeding or the medication since this drug may pass into breast milk. It is advisable not to use this medication in children under 18 years of age as its safety and efficacy have not been established in this population. Elderly patients should start with a low dose and adjust carefully due to the possibility of decreased kidney and liver function. In case of overdose, hypotension and impaired cardiac function may occur; immediate medical help should be sought for appropriate treatment. This medication should be stored in a tightly sealed container, away from moisture and heat, and out of reach of children.
Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory reduction, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle stiffness, limb pain, low back pain, polyuria, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decrease in hemoglobin and hematocrit, cholelithiasis, female breast neoplasm, exacerbation of cerebral infarction, gum bleeding, orthostatic dizziness, chest pain, cold, increased CRP, fever, hemoptysis, excessive sneezing, runny nose, laryngitis, arthritis, flank pain, generalized pain, hypoglycemia, weight loss, heartburn, gastroenteritis, shingles, diplopia, insomnia, asthenia, angioedema, chronic malabsorption syndrome - similar intestinal disease, intestinal vascular edema, rhabdomyolysis, acute kidney failure, hair loss, pruritus, autoimmune hepatitis, angioedema, leukopenia, thrombocytopenia, toxic epidermal necrolysis, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, jaundice, elevated liver enzymes, hypotension, tachycardia, bradycardia, non-cardiogenic pulmonary edema
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress. The recommended storage temperature is between 1°C and 30°C at room temperature.
White round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.